Monjri M Shah
Overview
Explore the profile of Monjri M Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dilley S, Erickson B, Phillips C, Kennemer C, Zhang B, Matin T, et al.
Gynecol Oncol
. 2018 Apr;
149(1):49-52.
PMID: 29605050
Background: Population-based studies of women with epithelial ovarian cancer suggest that black women have worse survival compared to white women. The primary objective of this study was to determine if,...
2.
Shah M, Leath 3rd C, Daily L, McGwin Jr G, Estes J, Alvarez R, et al.
Int J Gynecol Cancer
. 2015 May;
25(5):798-801.
PMID: 25950127
Objective: To evaluate the potential impact of a standardized preoperative algorithm on outcomes of patients with suspected ovarian cancer. Methods: From January 1 to December 31, 2013, patients with suspected...
3.
Shah M, Erickson B, Matin T, McGwin Jr G, Martin J, Daily L, et al.
Gynecol Oncol
. 2014 Sep;
135(2):273-7.
PMID: 25220626
Objective: Diabetes mellitus (DM) is a risk factor for endometrial cancer and is associated with poorer outcomes in breast and colon cancers. This association is less clear in epithelial ovarian...
4.
Dobbin Z, Katre A, Steg A, Erickson B, Shah M, Alvarez R, et al.
Oncotarget
. 2014 Sep;
5(18):8750-64.
PMID: 25209969
A cornerstone of preclinical cancer research has been the use of clonal cell lines. However, this resource has underperformed in its ability to effectively identify novel therapeutics and evaluate the...
5.
Shah M, Dobbin Z, Nowsheen S, Wielgos M, Katre A, Alvarez R, et al.
Gynecol Oncol
. 2014 May;
134(2):331-7.
PMID: 24844596
Objective: BRCA-positive ovarian cancer patients derive benefit PARP inhibitors. Approximately 50% of ovarian cancer tumors have homologous recombination (HR) deficiencies and are therefore "BRCA-like," possibly rendering them sensitive to PARP...
6.
Erickson B, Martin J, Shah M, Straughn Jr J, Leath 3rd C
Gynecol Oncol
. 2014 Feb;
133(2):142-6.
PMID: 24517876
Objective: The National Comprehensive Cancer Network (NCCN) has established guidelines for treating epithelial ovarian cancer (EOC) which includes cytoreductive surgery and platinum and taxane-based chemotherapy (CT). The objective of this...
7.
Shah M, Landen C
Gynecol Oncol
. 2013 Dec;
132(2):483-9.
PMID: 24321398
The cancer stem cell hypothesis has been put forward as a paradigm to describe varying levels of aggressiveness in heterogeneous tumors. Specifically, many subpopulations have been clearly demonstrated to possess...
8.
Shine M, Shah M, Hanna C, Bevis K
Obstet Gynecol
. 2013 Jul;
122(2 Pt 2):449-452.
PMID: 23884256
Background: Histoplasmosis is an infection caused by the dimorphic fungus Histoplasma capsulatum and primarily presents with pulmonary symptoms. Immunocompromised individuals are at high risk for contracting disseminated histoplasmosis, which can...
9.
Shah M, Zerlin M, Li B, Herzog T, Kitajewski J, Wright J
Anticancer Res
. 2013 Mar;
33(3):801-8.
PMID: 23482747
Background: The Notch pathway is dysregulated in ovarian cancer. We sought to examine the role of Notch and gamma-secretase (GS) inhibition in ovarian cancer. Materials And Methods: Established ovarian cancer...
10.
Ziebarth A, Nowsheen S, Steg A, Shah M, Katre A, Dobbin Z, et al.
Clin Cancer Res
. 2012 Nov;
19(1):170-82.
PMID: 23147994
Purpose: Endoglin (CD105) is a membranous protein overexpressed in tumor-associated endothelial cells, chemoresistant populations of ovarian cancer cells, and potentially stem cells. Our objective was to evaluate the effects and...